Breast cancer in Japanese men: Does sex affect prognosis?

Anan, Keisei; Mitsuyama, Shoshu; Nishihara, Kazuyoshi; Abe, Yuji; Iwashita, Takuya; Ihara, Takaaki; Tamae, Keiyoshi; Ōno, Minoru; Toyoshima, Satoshi

doi:10.1007/bf02968299

Cited by 16 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A Chinese study of 35 MBC and 70 matched FBC showed the latter had significantly better overall survival at 5 and 10 years, but when the comparison was restricted to female postmenopausal, outcomes were similar [36]. Despite a small number of cases in the male arm and unbalanced cohort size, a Japanese study of 14 MBC and 140 FBC showed no difference in overall survival [37]. This was also reflected in a UK study comparing outcome in 41 MBC and 123 FBC which showed that when matched for key prognostic factors (size, grade and lymph node status), outcome was similar between genders [38], agreeing with our study.…”

Section: Discussionmentioning

confidence: 96%

A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences

Shaaban

Ball

Brannan

et al. 2011

Breast Cancer Res Treat

116

View full text Add to dashboard Cite

Male breast cancer remains understudied despite evidence of rising incidence. Using a co-ordinated multi-centre approach, we present the first large scale biomarker study to define and compare hormone receptor profiles and survival between male and female invasive breast cancer. We defined and compared hormone receptor profiles and survival between 251 male and 263 female breast cancers matched for grade, age, and lymph node status. Tissue microarrays were immunostained for ERα, ERβ1, -2, -5, PR, PRA, PRB and AR, augmented by HER2, CK5/6, 14, 18 and 19 to assist typing. Hierarchical clustering determined differential nature of influences between genders. Luminal A was the most common phenotype in both sexes. Luminal B and HER2 were not seen in males. Basal phenotype was infrequent in both. No differences in overall survival at 5 or 10 years were observed between genders. Notably, AR-positive luminal A male breast cancer had improved overall survival over female breast cancer at 5 (P = 0.01, HR = 0.39, 95% CI = 0.26-0.87) but not 10 years (P = 0.29, HR = 0.75, 95% CI = 0.46-1.26) and both 5 (P = 0.04, HR = 0.37, 95% CI = 0.07-0.97) and 10 years (P = 0.04, HR = 0.43, 95% CI = 0.12-0.97) in the unselected group. Hierarchical clustering revealed common clusters between genders including total PR-PRA-PRB and ERβ1/2 clusters. A striking feature was the occurrence of ERα on distinct clusters between genders. In female breast cancer, ERα clustered with PR and its isoforms; in male breast cancer, ERα clustered with ERβ isoforms and AR. Our data supports the hypothesis that breast cancer is biologically different in males and females suggesting implications for clinical management. With the incidence of male breast cancer increasing this provides impetus for further study.

show abstract

Section: Discussionmentioning

confidence: 96%

A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences

Shaaban

Ball

Brannan

et al. 2011

Breast Cancer Res Treat

116

View full text Add to dashboard Cite

show abstract

“…Exclusion criteria for the study included patients with carcinoma in situ or with history of other tumors, presence of metastatic lesions at initial diagnosis and patients who were operated in other institutions. Matching criteria included pathology of invasive ductal carcinoma in MBC and FBC, age at diagnosis (±5 years), year of diagnosis (±5 years) (6,7) and identical stage of the primary cancer at diagnosis. The females were selected from a total of 5,964 consecutive patients whose data were recorded in the same database and who underwent treatment at our institution during the same period.…”

Section: Methodsmentioning

confidence: 99%

Male breast cancer: A retrospective study comparing survival with female breast cancer

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

Abstract.Male breast cancer is a rare disease. The aim of this study was to compare overall survival (OS) and disease-free survival (DFS) in a group of matched males and females with breast cancer. The clinical data and survival status of 42 operable male breast cancer (MBC) cases treated at the Central Hospital of Tai'an from 1982 to 2006 were collected. Each MBC patient recorded in the database was matched with two female breast cancer (FBC) patients. Matching was conducted based on age, year of diagnosis, stage and pathology. SPSS 16.0 software was used for statistical analysis. The Chi-square test was used for the categorical data, the Kaplan-Meier method was applied to analyze survival and the log-rank test was used to compare curves between the groups. P<0.05 was considered to indicate a statistically significant difference. The 42 MBC patients were matched with 84 FBC patients. The mean age at diagnosis was 58.0±11.3 years for males and 57.1±10.6 years for females, and the median follow-up time was 64 months (range, 5-262 months) for males and 71 months (range, 29-283 months) for females. Significant differences were identified for tumor location, hormone receptor status, adjuvant chemotherapy and hormone therapy between the two groups. Monofactorial analysis demonstrated that tumor size, lymph node status and AJCC stage were prognostic factors in MBC patients. The 5-and 10-year DFS rates were 61.2 and 40.7% for males, and 68.7 and 43.0% for females, respectively. The 5-and 10-year OS rates were 75.3 and 52.3% for males, and 82.9 and 63.2% for females, respectively. In our study, male breast carcinoma patients had a worse prognosis compared to female breast carcinoma patients which may be due to the deficiency of adjuvant chemotherapy and endocrine therapy.

show abstract

“…(10) This has led to the notion that a more aggressive treatment strategy is needed for men with breast cancer. The controversy continues, however, because some researchers found no association between the sex of the patient and survival, (11)(12)(13)(14)(15)(16)(17)(18)(19)(20) or even demonstrated that men had longer survival. (21) Apart from varying strategies for selection of the study population, insufficient sample sizes might explain these divergent findings.…”

mentioning

confidence: 99%

Survival of male breast cancer patients: Population‐based cohort study

Thalib

Hall

2009

Cancer Science

View full text Add to dashboard Cite

Little information is available on the survival of male breast cancer patients because the disease is extremely rare in men. Moreover, previous reports on the prognosis of male breast cancer have been conflicting. We took advantage of a number of large, nationwide registries in Sweden to evaluate the prognostic value of sex in breast cancer patients. A population-based cohort of 269 male and 30 011 female breast cancer patients born after 1935 and diagnosed with primary breast cancer between 1970 and 1997 was generated by linking a number of Swedish registries, including the Swedish Cancer Registry, the Cause of Death Registry, the Swedish Generation Registry, and the Registry of Population and Population Changes. We used this cohort to quantify the association between the sex of the patient and breast cancer-specific mortality, using the Cox proportional hazards. The sex of the patient did not significantly influence the prognosis of breast cancer. Adjusting for age at diagnosis and calendar period did not alter the results. Nor did the results change when the analyses were repeated for all causes of morality. Our study, one of the largest to date, failed to find evidence to support the proposed association between the sex of breast cancer patients and survival. Given the previous reports, which advocated that male breast cancer patients have poorer survival and need aggressive treatment strategies, our findings are reassuring and clinically very important.

show abstract

Breast cancer in Japanese men: Does sex affect prognosis?

Abstract: Survival rates of Japanese male and female breast cancer patients are similar when age and stage of the disease are taken into consideration. However, comorbid disease mortality is likely the major contributor to clinical outcome in Japanese male breast cancer.

Cited by 16 publications

References 25 publications

A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences

A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences

Male breast cancer: A retrospective study comparing survival with female breast cancer

Survival of male breast cancer patients: Population‐based cohort study

Contact Info

Product

Resources

About